Group 1 - The core viewpoint of the article highlights that SenSong International (02155) has seen a significant stock price increase, rising over 8% and reaching HKD 9.08, with a trading volume of HKD 22.42 million [1] - According to a report from Cinda Securities, the domestic market is expected to return to rationality starting in the second half of 2024, with gross margins gradually recovering to reasonable levels. This recovery is anticipated to be driven by a rebound in innovative drug financing and frequent BD transactions, leading to a revival in the CMO sector, which will gradually impact the pharmaceutical equipment industry and potentially achieve a cyclical reversal [1] - Open Source Securities reports that SenSong International, as a global leader in high-end pressure equipment, will benefit from the recovery of CAPEX in the pharmaceutical industry and the expansion demands from overseas MNCs. The company has seen rapid growth in new orders, with the release of Phase II capacity in Malaysia shortening project cycles. Additionally, the acquisition of Pharmadue and Bioenhance has strengthened its biopharmaceutical capabilities, while the "MVP" digital solutions are driving rapid performance growth [1]

Group 1 - The core viewpoint of the article highlights that SenSong International (02155) has seen a significant stock price increase, rising over 8% and reaching HKD 9.08, with a trading volume of HKD 22.42 million [1] - According to a report from Cinda Securities, the domestic market is expected to return to rationality starting in the second half of 2024, with gross margins gradually recovering to reasonable levels. This recovery is anticipated to be driven by a rebound in innovative drug financing and frequent BD transactions, leading to a revival in the CMO sector, which will gradually impact the pharmaceutical equipment industry and potentially achieve a cyclical reversal [1] - Open Source Securities reports that SenSong International, as a global leader in high-end pressure equipment, will benefit from the recovery of CAPEX in the pharmaceutical industry and the expansion demands from overseas MNCs. The company has seen rapid growth in new orders, with the release of Phase II capacity in Malaysia shortening project timelines. Additionally, the acquisition of Pharmadue and Bioenhance has strengthened its biopharmaceutical capabilities, while the "MVP" digital solutions are driving significant performance growth [1]